These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17158554)

  • 1. Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy: what is the appropriate use of filgrastim?
    Ferretti G; Lopez M; Terzoli E; Cortesi E; Antimi M; Marolla P; Giannarelli D; Cognetti F; Papaldo P
    J Clin Oncol; 2006 Dec; 24(35):5618-9. PubMed ID: 17158554
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
    Papaldo P; Lopez M; Marolla P; Cortesi E; Antimi M; Terzoli E; Vici P; Barone C; Ferretti G; Di Cosimo S; Carlini P; Nisticò C; Conti F; Di Lauro L; Botti C; Di Filippo F; Fabi A; Giannarelli D; Calabresi F
    J Clin Oncol; 2005 Oct; 23(28):6908-18. PubMed ID: 16129844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can the addition of prophylactic filgrastim be considered cost effective in early breast cancer patients treated with epirubicin and cyclophosphamide?
    Ferretti G; Papaldo P
    J Clin Oncol; 2006 Dec; 24(35):5615-6; author reply 5616. PubMed ID: 17158552
    [No Abstract]   [Full Text] [Related]  

  • 4. Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial.
    Romieu G; Clemens M; Mahlberg R; Fargeot P; Constenla M; Schütte M; Easton V; Skacel T; Bacon P; Brugger W
    Crit Rev Oncol Hematol; 2007 Oct; 64(1):64-72. PubMed ID: 17317205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The feasibility of FEC (75) as adjuvant chemotherapy for Japanese breast cancer patients].
    Kim SJ; Taguchi T; Miyoshi Y; Tanji Y; Tamaki Y; Noguchi S
    Gan To Kagaku Ryoho; 2005 Nov; 32(12):1919-23. PubMed ID: 16282727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.
    Fornier MN; Seidman AD; Lake D; D'Andrea G; Bromberg J; Robson M; Van Poznak C; Panageas KS; Atienza M; Norton L; Hudis C
    Clin Cancer Res; 2007 Jan; 13(1):223-7. PubMed ID: 17200358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of G-CSF for breast cancer chemotherapy].
    Suzuki Y; Saito Y; Tokuda Y
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():572-4. PubMed ID: 17679213
    [No Abstract]   [Full Text] [Related]  

  • 8. Adjuvant chemotherapy with TAC (docetaxel, doxorubicin, and cyclophosphamide) in patients with breast cancer--incidence of neutropenic fever outside clinical trials.
    Passos-Coelho JL; Esteves S; Vieira PA; Isidoro M; Ribeiro M; Oliveira J; Moreira AR
    Breast J; 2011; 17(5):539-41. PubMed ID: 21899649
    [No Abstract]   [Full Text] [Related]  

  • 9. [The whole dose at once?].
    Rodríguez García J; Ramos Ortega FJ; Sandoval Guerra V; García Sanz R
    Sangre (Barc); 1996 Jun; 41(3):259. PubMed ID: 8755216
    [No Abstract]   [Full Text] [Related]  

  • 10. Dose-rounding of adjuvant chemotherapy for breast cancer: an audit of toxicity.
    Jenkins P; Wallis R
    J Oncol Pharm Pract; 2010 Dec; 16(4):251-5. PubMed ID: 19965948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effectiveness of Leukostim, a Russian preparation of granulocyte colony-stimulating factor, in the treatment of chemotherapy-induced neutropenia in patients with malignant tumors].
    Korman DB; Boronovskaia LE; Maslova IA; Andreeva EV; Seregina GV
    Vopr Onkol; 2008; 54(5):639-42. PubMed ID: 19069482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support.
    Wolff AC; Jones RJ; Davidson NE; Jeter SC; Stearns V
    J Clin Oncol; 2006 May; 24(15):2392-4; author reply 2394-5. PubMed ID: 16710041
    [No Abstract]   [Full Text] [Related]  

  • 13. Improved outcomes from dose-dense adjuvant chemotherapy for breast cancer with growth factor support.
    Leonard JP
    Curr Hematol Rep; 2003 Nov; 2(6):451-2. PubMed ID: 14561387
    [No Abstract]   [Full Text] [Related]  

  • 14. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.
    von Minckwitz G; Schwenkglenks M; Skacel T; Lyman GH; Pousa AL; Bacon P; Easton V; Aapro MS
    Eur J Cancer; 2009 Mar; 45(4):608-17. PubMed ID: 19110415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
    Papadimitriou CA; Papakostas P; Timotheadou E; Aravantinos G; Bamias A; Fountzilas G
    Cancer Invest; 2008 Jun; 26(5):491-8. PubMed ID: 18568771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.
    Skarlos DV; Timotheadou E; Galani E; Samantas E; Grimani I; Lianos E; Aravantinos G; Xanthakis I; Pentheroudakis G; Pectasides D; Fountzilas G
    Oncology; 2009; 77(2):107-12. PubMed ID: 19622901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose density in breast cancer: a simple message?
    Lin NU; Gelman R; Winer EP
    J Natl Cancer Inst; 2005 Dec; 97(23):1712-4. PubMed ID: 16333021
    [No Abstract]   [Full Text] [Related]  

  • 18. [Prevention of neutropenia during adjuvant taxotere therapy for breast cancer].
    Mochalova AS; Koroleva IA
    Vopr Onkol; 2012; 58(6):813-6. PubMed ID: 23600309
    [No Abstract]   [Full Text] [Related]  

  • 19. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
    Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
    J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Filgrastim and lack of support of intensive adjuvant chemotherapy for high-risk breast cancer patients.
    Baldini E; Tibaldi C; Lencioni M; Giannessi P; Evangelista G; Roncella M; Spinelli C; Meucci C; da Prato M; Conte P
    Am J Clin Oncol; 1997 Apr; 20(2):169-72. PubMed ID: 9124194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.